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ABSTRACT
We have synthesized a series of 2-aminoethoxydiphenyl borate
(2-APB, 2,2-diphenyl-1,3,2-oxazaborolidine) analogs and
tested their ability to inhibit thrombin-induced Ca2 influx in
human platelets. The analogs were either synthesized by add-
ing various substituents to the oxazaborolidine ring (methyl,
dimethyl, tert-butyl, phenyl, methyl phenyl, and pyridyl) or in-
creasing the size of the oxazaborolidine ring to seven- and
nine-membered rings. NMR analysis of the boron-containing
analogs suggests that each of them exist as a ring structure
through the formation of an N3B coordinate bond (except for
the hexyl analog). The possibility that these boron-containing
compounds formed dimers was also considered. All com-
pounds dose-dependently inhibited thrombin-induced Ca2 in-
flux in human platelets, with the 2,2-diphenyl-1,3,2-oxazaboro-
lidine-5-one derivative having the weakest activity at 100 M,
whereas the (S)-4-benzyl and (R)-4-benzyl derivatives of 2-APB
were approximately 10 times more potent than the parent
2-APB. Two nonboron analogs (3-methyl and 3-tert-butyl 2,2-
diphenyl-1,3-oxazolidine) were synthesized; they had approxi-
mately the same activity as 2-APB, and this implies that the
presence of boron was not necessary for inhibitory activity. All
of the compounds tested were also able to inhibit thrombin-
induced calcium release. We concluded that extensive modifi-
cations of the oxazaborolidine ring in 2-APB can be made, and
Ca2-blocking activity was maintained.
2-Aminoethoxydiphenyl borate (2-APB; systematic name:
2,2-diphenyl-1,3,2-oxazaborolidine, compound 1) was origi-
nally described as an inhibitor of inositol 1,4,5-trisphosphate
receptors (IP3R) in a variety of cells (Maruyama et al., 1997)
and has been extensively used as a probe for examining
calcium influx processes. 2-APB was inappropriately used in
several studies to imply that IP3Rs were involved in store-
operated Ca2 entry (SOCE) (Ma et al., 2000; van Rossum et
al., 2000). For a review of our current understanding of the
nature of SOCE and how the SOCE channels are regulated,
see Parekh and Putney (2005). It has been suggested that
SOCE is mediated by members of the transient receptor
potential canonical (TRPC), family although this has not
been accepted universally (Parekh and Putney, 2005).
Upon further investigation, it became evident that 2-APB,
along with inhibition of IP3Rs, was also inhibiting SOCE
directly in several cell types (Bakowski et al., 2001; Braun et
al., 2001; Broad et al., 2001; Diver et al., 2001; Dobrydneva
and Blackmore, 2001; Dobrydneva et al., 2001, 2002; Gregory
et al., 2001; Iwasaki et al., 2001; Ma et al., 2001; Prakriya
and Lewis, 2001; Bootman et al., 2002). The inhibition of
SOCE seemed to be at an extracellular site by a mechanism
not involving intracellular IP3Rs. In our study showing that
2-APB blocked SOCE in human platelets (Dobrydneva and
Blackmore, 2001), we tested whether several other structur-
ally related compounds were also inhibitors of SOCE. We
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found that the nonboron analog of 2-APB, 2,2-diphenyltetra-
hydrofuran, and diphenylboronic anhydride also inhibited
both calcium mobilization and calcium influx (Dobrydneva
and Blackmore, 2001). Two other nonboron analogs, pheny-
toin and diphenhydramine, were very weak inhibitors of
calcium influx. From this limited structural analysis, it
seemed that compounds with calcium-blocking activity pos-
sessed diphenyl groups; also, the presence of a saturated
five-membered ring structure was needed. The presence of
boron in the structure was not an absolute requirement,
although boron and nitrogen were necessary for ring forma-
tion through an N3B coordinate bond (Fig. 1). It has also
been proposed that 2-APB forms a dimer (Fig. 1) (van Ros-
sum et al., 2000). 2-APB, at high concentrations, has also
been shown to activate TRPV1, TRPV2, and TRPV3, three
heat-gated members of the transient receptor potential va-
nilloid ion-channel subfamily (Hu et al., 2004). 2,2-Diphe-
nyltetrahydrofuran and diphenylboronic anhydride (Dobryd-
neva and Blackmore, 2001) were also able to modulate the
activity of these channels (Chung et al., 2005).
The calcium channel responsible for store-mediated cal-
cium entry in human platelets is believed to be TRPC1
(Brownlow and Sage, 2003). The regulation of this entry
process seems to be very complex and possibly involves the
conformational coupling between the IP3R in the endoplas-
mic reticulum and the store-operated calcium channels lo-
cated in the plasma membrane (Rosado and Sage, 2005).
There is evidence for the involvement of synaptosome-asso-
ciated protein-25, pp60src, the actin cytoskeleton, and extra-
cellular regulated kinase in this process (Rosado and Sage,
2001, 2004a,b; Redondo et al., 2004). Patch-clamp experi-
ments have shown that 2-APB acts extracellularly on various
TRP channels (Xu et al., 2005), so it reasonable to assume
that 2-APB also acts extracellularly on TRPC1 in platelets.
However, 2-APB could also be interacting with any of the
other components that regulate TRPC1 activity such as ex-
tracellular regulated kinase, pp60src, and synaptosome-asso-
ciated protein-25 (Rosado and Sage, 2001, 2004a,b; Redondo
et al., 2004).
The aim of the present study was to synthesize a series of
boron-containing and nonboron-containing analogs of 2-APB
to determine whether we could obtain compounds more po-
tent than the parent 2-APB at inhibiting Ca2 influx in
human platelets. We anticipated that this series of com-
pounds would shed light onto the structure of the pharma-
cophore that was responsible for calcium-blocking activity.
We succeeded in synthesizing several analogs that were as
effective as the parent 2-APB, and two boron-containing com-
pounds that were more potent than 2-APB at inhibiting Ca2
influx in platelets.
Materials and Methods
Materials. The following were obtained from Sigma-Aldrich (St.
Louis, MO): 2-aminoethoxydiphenyl borate, 2-(methylamino)etha-
nol, 2-(t-butylamino)ethanol, 2-amino-1-phenylethanol, 4-amino-1-
butanol, 6-amino-1-hexanol, diphenylborinic anhydride, the sodium
salt of glycine, ethanolamine, dimethyl sulfoxide, benzophenone,
phosphorus pentachloride, and EGTA. 3,3-Diphenyl dihydrofuran-2-
one (trivial name: ,-diphenyl--butyrolactone) was from Acros Or-
ganics (Fairlawn, NJ). All organic solvents were from Fisher Scien-
tific Co. (Pittsburgh, PA). Fura-2/AM was from Invitrogen (Carlsbad,
CA).
Synthesis of 2-APB Analogs. All melting points were deter-
mined with a Thomas Hoover Capillary Melting Point Apparatus
(Thomas Scientific, Swedesboro, NJ) and are uncorrected. 1H NMR
spectra were determined in a UnityPlus-400 MHz instrument oper-
ating at a field strength of 399.89 MHz or a Varian Mercury Vx-400
spectrometer (Varian, Inc., Palo Alto, CA). All carbon, hydrogen, and
nitrogen analyses were performed by Desert Analytics (Tucson, AZ).
A general method was developed for the synthesis of 2-APB and the
various 2-APB analogs, which is described for each compound. The
method involved a reaction between diphenylborinic anhydride and
a corresponding amino alcohol. The synthesis of 2,2-diphenyl-1,3,2-
oxazaborolidine (1) and (S)-4-benzyl-2,2-diphenyl-1,3,2-oxazaboroli-
dine (11) are shown in Fig. 2. All of the reaction solutions were
allowed to stir in an ice bath until precipitation occurred (no more
than 1 h), then they were chilled in an ice bath undisturbed for an
additional 15 min, which increased the amount of precipitation. All
of the products were purified by recrystallization using ethyl acetate
as the solvent, except for 2,2,5-triphenyl-1,3,2-oxazaborolidine (8),
which was recrystallized using benzene. All of the products were
white solids with sharp melting points. Monomeric structures with
an internal N3B coordinate bond are shown for all compounds
synthesized (Fig. 3). Because we have depicted 2-APB and its deriv-
atives as ring structures in this study, then the commonly used name
2-aminoethoxydiphenyl borate does not describe this ring system.
We have therefore used the 1983 IUPAC Hantzsch-Widman system
to name the ring forms of 2-APB and its derivatives. The numbering
order of the heteroatoms in the oxazaborolidine ring is oxygen num-
ber 1, nitrogen number 2, and boron number 3; hence, the numbering
of this ring is 1,3,2-oxazaborolidine in 2-APB.
2,2-Diphenyl-1,3,2-oxazaborolidine (1). Ethanolamine (0.02 g)
was added to 0.10 g of diphenylborinic anhydride in 4 ml of acetoni-
trile. The solution was stirred for 1 h without any signs of precipi-
tation. The solution was refrigerated for 15 h in which the product
precipitated and was filtered to give 0.056 g of compound 1 (75%
yield). The melting point was 193 to 194°C (literature, 190–192°C).
1H NMR (d6-DMSO): 2.83 (p, CH2), 3.77 (CH2), 6.07 (broad t, NH2),
7.01 (m, 2H), 7.14 (m, 4H), and 7.39 (m, 4H). The broad triplet at 6.07
caused by the NH2 rapidly exchanged with the addition of D2O.
3-Methyl-2,2-diphenyl-1,3,2-oxazaborolidine (2). 2-Methyl-
aminoethanol (0.05 g) was added to 0.20 g of diphenylborinic anhy-
Fig. 1. Structures of 2-APB: open-chain form, five-membered (1,3,2-
oxazaborolidine) ring form created when an N3B coordinate bond is
formed, and dimeric form produced when two N3B coordinate bonds are
formed between two molecules of 2-APB. Dimeric 2-APB could also exist
with the formation of only one N3B coordinate bond (structure not
shown).
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dride in 8 ml of acetonitrile. The product precipitated to give 0.066 g
of compound 2 (46% yield); melting point, 196 to 197.5°C. 1H NMR
(d6-DMSO):  2.16 (d, CH3), 2.64 (p, CH), 3.03 (p, CH), 3.75 (q, CH),
4.01 (q, CH), 6.67 (m, NH), 7.09 (t, 2H), 7.16 (t, 4H), and 7.46 (dd,
4H). Analysis: calculations for C15H18BNO: C, 75.33; H, 7.60; N, 5.86;
found, C, 75.32; H, 7.56; N, 5.68. The multiplet at 6.67 was for the
NH rapidly exchanged with the addition of D2O.
3,3-Dimethyl-2,2-diphenyl-1,3,2-oxazaborolidine (3). Diphe-
nylborinic anhydride (0.01 g) was stirred with 0.05 ml of dimethyl-
aminoethanol in 10 ml of acetonitrile. The product slowly precipi-
tated from solution to give 0.195 g of compound 3 (82% yield); melting
point, 165 to 166°C. 1H NMR (d6-DMSO): 2.50 (s, 6H, CH3), 2.92 (t,
CH2), 4.10 (t, CH2), 7.10 (m, 2H), 7.18 (m, 4H), and 7.65 (m, 4H).
3-tert-Butyl-2,2-diphenyl-1,3,2-oxazaborolidine (4). 2-tert-
Butylaminoethanol (0.07 g) was added to 0.20 g of diphenylborinic
anhydride in 8 ml of acetonitrile. The product precipitated to give
0.125g of compound 4 (76% yield); melting point, 133.1 to 134.0°C. 1H
NMR (d6-DMSO):  1.16 (s, CH3), 2.69 (t, CH2), 3.55 (t, CH2), 6.91 (tt,
NH), 6.98 (t, 2H), 7.06 (t, 4H), 7.44 (dd, 4H). Analysis: calculations
for C18H24BNO: C, 73.85; H, 8.62; N, 4.31; found: C, 73.31; H, 8.76;
N, 4.68. The peak at 6.91, assigned to the NH, rapidly exchanged
with the addition of D2O.
2,2,5-Triphenyl-1,3,2-oxazaborolidine (5). 2-Amino-1-phe-
nylethanol (0.08 g) was added to 0.20 g of diphenylborinic anhydride
in 8.0 ml of acetonitrile. The product precipitated to give 0.072 g of
compound 5 (41% yield); melting point, 194.9 to 196.0°C. 1H NMR
(d6-DMSO):  3.25 (q, CH2), 4.85 (dd, CH), 6.31 (t, NH2), 7.03 (t, 2H),
7.08 (t, 4H), 7.16 (dd, 4H), 7.25 (t, 2H), 7.34 (t, 4H), 7.49 (dd, 4H).
Analysis: calculations for C20H20BNO: C, 79.75; H, 6.69; N, 4.65;
found, C, 80.27; H, 6.62; N, 4.65. The triplet peak at 6.31 rapidly
exchanged with the addition of D2O.
Fig. 2. The general scheme for the synthesis of the diphenyl oxazaboro-
lidine analogs is shown. Two examples are shown. A, the synthesis of the
parent 2,2-diphenyl-1,3,2-oxazaborolidine (1) is shown, and the starting
reactants are diphenylborinic anhydride and ethanolamine. B, the syn-
thesis of (S)-4-benzyl-2,2-diphenyl-1,3,2-oxazaborolidine (11) is shown,
and the starting reactants in this synthesis are diphenylborinic anhy-
dride and (S)()2-amino-3-phenyl-1-propanol.
Fig. 3. Structures of compounds (1
through 14) synthesized in this study.
The method for the synthesis of each
compound is detailed in the text.
Compound 15 (3,3-diphenyl dihydro-
furan-2-one) was obtained from a
commercial source (ACROS). Com-
pounds 5, 8, 9, 11, and 12 contain a
chiral carbon atom. Compounds 5, 8,
and 9 are racemic mixtures.
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(0.053 g) was added to 0.20 g of diphenylborinic anhydride in 8.0 ml
of acetonitrile. The product precipitated from solution to give 0.020 g
of compound 6 (27% yield); melting point, 185.60 to 186.1°C. 1H NMR
(d6-DMSO):  1.58 (p, CH2), 1.67 (p, CH2), 2.71 (p, CH2), 3.59 (t, CH2),
5.82 (t, NH2), 7.01 (t, 2H), 7.12 (t, 4H), 7.45 (dd, 4H). Analysis:
calculations for C16H20BNO: C, 75.95; H, 7.98; N, 5.58; found: C,
76.47; H, 8.04; N, 5.59.
2,2-Diphenyl-1,3,2-oxazaboronane (7). 6-Amino-1-hexanol
(0.073 g) was added to 0.20 g of diphenylborinic anhydride in 8.0 ml
of acetonitrile. The product precipitated to give 0.228g of compound
7 (32% yield); melting point, 70.0 to 71.0°C. 1H NMR (d6-DMSO): 
1.28 (p, CH2), 1.35 (p, CH2), 1.42 (p, CH2), 1.63 (p, CH2), 2.63 (q,
CH2), 3.33 (broad s, NH2), 3.46 (t, CH2), 7.08 (t, 2H), 7.17 (t, 4H), 7.53
(dd, 4H). Analysis: calculations for C18H24BNO: C, 72.73; H, 8.26; N,
11.57; found: C, 72.33; H, 8.08; N, 11.04. The peak at 3.33 rapidly
exchanged with the addition of D2O.
2,2,5-Triphenyl-benzo[3,4]-1,3,2-oxazaborolidine (8). Sodium
borohydride (0.107 g) was added to 0.50 g of 2-acetylpyridine in 2.0
ml of methanol to yield 0.293 g of 2-(1-hydroxyethyl)pyridine after
stirring for 30 min. The precipitate was filtered out of the solution
using vacuum filtration and dried. 2-(1-Hydroxyethyl) pyridine
(0.283 g) was added to 0.825 g of diphenylborinic anhydride in 31.0
ml of acetonitrile. The product precipitated to yield 0.473 g of the
compound 8 (yield 69.2%); melting point, 200 to 201.1°C (literature
melting point, 199–200°C; Farfan et al., 1992).
5-Methyl-2,2-diphenyl-benzo[3,4]-1,3,2-oxazaborolidine (9).
A 0.277-g sample of 2-(1-hydroxyethyl)pyridine was stirred with
0.518 g of diphenylborinic anhydride in 30.0 ml of acetonitrile. The
product precipitated to give 0.381 g of compound 9 (72.8% yield);
melting point, 164.2 to 164.9°C (literature melting point, 164–165°C;
Farfan et al., 1992).
2,2-Diphenyl-1,3,2-oxazaborolidine-5-one (10). Diphenyl-
borinic anhydride (0.2 g), dissolved in 20.0 ml of acetonitrile, was
stirred at with 0.058 g of the sodium salt of glycine. The acetonitrile
was removed under nitrogen to give 0.238 g of compound 10 (45%
yield); melting point, 235 to 238°C. 1H NMR (d6-DMSO): 3.47 (t,
CH2), 7.09 (t, NH2), 7.17 (m, 2H), 7.23 (m, 4H), 7.39 (m, 4H). Anal-
ysis: calculations for C14H14BNO2: 70.43; H, 5.80; N, 5.86; found: C,
70.12; H, 5.83; N, 5.80. The triplet at 7.09 rapidly exchanged with the
addition of D2O.
(S)-4-Benzyl-2,2-diphenyl-1,3,2-oxazaborolidine (11). (S)()-
2-Amino-3-phenyl-1-propanol (0.50 g) was dissolved in 11.0 ml of
acetonitrile and treated with a solution of 1.14 g of diphenylborinic
anhydride in 9.0 ml of acetonitrile. The reaction was stirred for 1
week, and then the solvent was removed with nitrogen gas to give
0.556 g of compound 11 (60% yield); melting point, 129 to 135°C. 1H
NMR (d6-DMSO): 2.734 (dd, 1H), 2.94 (dd, 1H), 3.35 (m, 1H), 3.55 (t,
1H), 3.81 (t, 1H), 5.80 (t, 1H), 6.42 (t, 1H), 7.05 to 7.45 (mm, 15H).
Analysis: calculations for C21H22BNO: C, 80.0; H, 6.98; N, 4.45;
found: C, 79.89; H, 6.95; N, 4.54. The two triplets at 5.80 and 6.42 are
assigned to the two nonequivalent NH protons rapidly exchanged
with the addition of D2O.
(R)-4-Benzyl-2,2-diphenyl-1,3,2-oxazaborolidine (12). (R)()-
2-Amino-3-phenyl-1-propanol (0.50 g) was dissolved in 30.0 ml of
acetonitrile and treated with a solution of 1.14 g of diphenylborinic
anhydride in 9.0 ml of acetonitrile. The solution was stirred at for 4
days when the solvent was removed with nitrogen gas to give 0.510
g of compound 12 (55% yield); melting point, 120 to 125°C. 1H NMR
(d6-DMSO): 2.73 (dd, 1H), 2.94 (dd, 1H), 3.35 (t, 1H), 3.81 (t, 1H),
5.80 (t, 1H), 6.42 (t, 1H), 7.05 to 7.45 (mm, 15H). Analysis: calcula-
tions for C21H22BNO: C, 80.0; H, 6.98; N, 4.45; found: C, 79.66; H,
7.18; N, 5.25. The two triplets at 5.80 and 6.42 are assigned to the
two nonequivalent NH protons rapidly exchanged with the addition
of D2O.
Synthesis of Oxazolidine Analogs. Dichlorodiphenylmethane
was prepared from benzophenone and phosphorus pentachloride ac-
cording to the method of Staudinger and Freudenberger (1943).
3-Methyl-2,2-diphenyl-1,3-oxazolidine (13). Silver oxide (2.0 g,
8.6 mmol) was added to a mixture of dichlorodiphenylmethane (2.0 g,
9.4 mmol) and 2-(methylamino)ethanol (1.4 ml, 17 mmol). The mix-
ture was warmed on a hot plate until a violent reaction ensued
(Scheme 1). The mixture was cooled, and the solid residue was
washed repeatedly with hexanes. The combined filtrates were
washed with water, dried over sodium sulfate, filtered, and concen-
trated in vacuo. The residue was distilled under high vacuum. The
distillate was recrystallized from hexanes giving 0.87 g of compound
13 (3.6 mmol, 42% yield). NMR spectra were in agreement with
published data (Azzena et al., 1993).
3-tert-Butyl-2,2-diphenyl-1,3-oxazolidine (14). Silver acetate
(1.7 g, 10.2 mmol) was added to a mixture of dichlorodiphenylmeth-
ane (1.0 g, 4.7 mmol) and 2-(tert-butylamino)ethanol (5.5 g, 47
mmol). The mixture was warmed on a hotplate for 30 min during
which a brown solid appeared (Scheme 2). The reaction was allowed
to cool, and the solid was washed with hexanes (100 ml). The hexane
filtrate was washed three times with water (100 ml each), dried over
sodium sulfate, and concentrated in vacuo. Crystals formed slowly
upon standing, which were placed on an absorbant tissue to remove
the benzophenone side-product that remains in the melt. The prod-
uct 14 thus obtained was 230 mg (0.82 mmol, 17% yield) with a
melting point of 66 to 68°C. 1H NMR (CDCl3):  7.59 (m, 4H), 7.27 (m,
6H), 3.76 (t, J 6.5 Hz, 2H), 3.31 (t, J 6.5 Hz, 2H), 0.92 (s, 9H); 13C
NMR (CDCl3):  144.5, 129.6, 127.5, 127.3, 99.7, 63.0, 54.5, 47.6,
29.9. The compound was sublimed under vacuum for analysis. Anal-
ysis: calculations for C19H23NO: C, 81.10; H, 8.24; N, 4.98; found: C,
80.98; H, 8.33; N, 4.81.
2,2-Diphenyl-1,3-oxazolidine (16).We were unable to isolate 2,
2-diphenyl-1,3-oxazolidine (compound 16), which is the carbon ana-
log of the ring form of 2-APB, where the boron is replaced by a
carbon. Results from the parent oxazolidine are therefore not re-
ported. The compound, however, was successfully prepared by the
condensation of ethanol amine with benzophenone imine. Neverthe-
less, the oxazolidine 16 exists as an equilibrium mixture with its
ring-opened 17 tautomer (Fig. 4). Proton NMR analysis suggests a
ratio of 14:86 in favor of the ring-opened form. The evidence for the
ring-opened structure is the nonequivalence of the phenyl rings. The
phenyl rings in the ring-open tautomer are diastereomeric because
the imine double bond. The 1H NMR shows four sets of strong
aromatic resonances at 7.62, 7.46, 7.34, and 7.17 ppm. The ring-
closed structure should show only two strong signals for the sets of
Scheme 1.
Scheme 2.
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four equivalent ortho and meta hydrogens, respectively. In the ali-
pahtic region, there are two pairs of triplets. The major pair occurs at
3.84 and 3.48 ppm, whereas the minor pair occurs at 3.85 (obscured
by the major isomer) and 3.15 ppm. The methylenes adjacent to the
nitrogen are the upfield resonances of each set. The imine structure
of the ring-opened isomer gives rise to the shift from 3.15 to 3.48
ppm. Finally, the chemical shifts of the aliphatic protons of the
ring-closed methyl derivative 13 are similar to those of the minor
isomer. Precedent for ring-opening tautomerization has been re-
ported. Thus, the oxazoline from acetophenone and ethanolamine
exists as a 50:50 mixture with the ring-opened form (Konkova et al.,
1999). It is reasonable to suggest that the conjugation provided by
the extra phenyl ring in benzophenone results in a greater propor-
tion of the imine form.
Blood Donors and Platelet Preparation. All donors were
healthy nonsmoking volunteers (age 20–60 years) who had not con-
sumed any medication known to affect platelet function (e.g., calci-
um-channel blockers and aspirin) for at least 10 days before the
study. Venous blood was collected into 1/10 volume of (74.8 mM
sodium citrate, 38.1 mM citric acid, and 123 mM dextrose, pH 6.4)
(Baxter, McGaw Park, IL). The blood was centrifuged at 250g for 10
min at room temperature to obtain platelet-rich plasma. The plate-
let-rich plasma was centrifuged at 550g for 12 min to sediment the
platelets. The platelets were then resuspended in a modified Ty-
rode’s physiological salt solution (145 mM NaCl, 4 mM KCl, 1 mM
MgSO4, 0.5 mM Na2HPO4, 10 mM sodium-HEPES and 6 mM glu-
cose, pH 7.4) containing 1.0 mM EGTA to prevent spontaneous
aggregation during the various experimental manipulations by bind-
ing extracellular Ca2.
Platelet Loading with Fura-2 and Measurement of [Ca2]i.
Intracellular calciummeasurements [Ca2]i used the fluorescent dye
Fura-2, which involved incubating the platelets with the cell-per-
meant acetoxymethyl ester (Fura-2/AM). Suspensions of human
platelets (isolated as described above) were incubated with 2 M
Fura-2/AM for 1 h at room temperature (on a rocking platform).
Excess Fura-2/AM was removed by centrifugation (500g for 10 min),
and the platelets were suspended in modified Tyrode’s buffer without
added EGTA. Aliquots of platelet suspension (0.5 ml) were added to
1-ml cuvettes containing a Teflon-coated stirrer bar (CHRONO-LOG,
Havertown, PA). To measure intracellular Ca2 mobilization, Ca2
was not added to the platelet suspension; test compounds were added
at approximately 10 s, then at 20 s, 0.01 units/ml thrombin was
added. To evaluate Ca2 influx, approximately 30 s before [Ca2]i
measurements were performed, Ca2was added back to the buffer to
a final concentration of 2.0 mM, and then test compounds were
dissolved in Me2SO (various concentrations in 2.5 l), and thrombin
0.01 units/ml were added. The measurements of [Ca2]i was per-
formed at room temperature in a SPEX ARCM spectrofluorometer
(SPEX Industries, Edison, NJ) using excitation wavelengths of 340
and 380 nm and an emission wavelength of 505 nm. Calibration was
performed as described previously (Dobrydneva and Blackmore,
2001). [Ca2]i was calculated by using the SPEX dM3000 software.
The data in Fig. 5 show a typical experiment. To calculate the
percentage of inhibition of thrombin effects by the various analogs,
the [Ca2]i before thrombin addition was measured; then, the [Ca
2]i
was measured after the thrombin effect had reached a maximum
value (which was approximately after 1 min). The difference was
then compared with the effect observed in the absence of any inhib-
itor (control), which represents 0% inhibition.
Results and Discussion
Chemistry. All of the 2-APB analogs that we synthesized
were obtained in 27 to 76% yields after purification by re-
crystallization. The reactions were temperature-dependent,
leading to high yields at cool temperatures and low yields at
warm temperatures. It is believed that the low yields at
warm temperatures could be caused by the acetonitrile re-
acting with the diphenylboronic anhydride before the amine
could be added. A possible product may be the acetonitrile
adduct of diphenylboronic anhydride, formed when the un-
paired electrons of acetonitrile forms an N3B coordinate
bond (Fig. 6). This finding illustrates one possible pitfall
when synthesizing boron-containing compounds in the pres-
ence of solvents (e.g., acetonitrile) or reactants with unpaired
electrons that could form coordinate bonds. At warm temper-
atures, the solution of acetonitrile and anhydride developed a
golden color, whereas at cooler temperatures, the solution
remains colorless, which suggests some involvement of the
solvent acetonitrile. To avoid the contamination of the prod-
uct produced when acetonitrile and diphenylboronic anhy-
dride react, the reaction vessel was placed in an ice bath for
the duration of the reaction, and the recrystallizing solvents
Fig. 4. Structures of the proposed tautomeric forms of the nonboron
analog of 2-APB, 2,2-diphenyl-1,3-oxazolidine (16), and 2-(diphenylmeth-
yleneamino)ethanol (17). The formation of compounds 16 and 17 involved
condensing ethanol amine with benzophenone imine after deamination of
the 2-(aminodiphenylmethylamino)ethanol intermediate.
Fig. 5. The effect of (S)-4-benzyl-2,2-diphenyl-1,3,2-oxazaborolidine (11)
on the ability of thrombin to increase [Ca2]i in the presence of extracel-
lular calcium. Extracellular calcium 2.0 mM was added to the platelet
suspension 30 s before data collection was started. Approximately 10 s
after data collection was commenced, various concentrations (1, 10, and
100 M) of (S)-4-benzyl-2,2-diphenyl-1,3,2-oxazaborolidine (11) were
added to the platelet suspension. Thrombin (0.01 units/ml) was added
approximately 10 s later. A representative experiment is shown, The
ability of thrombin to increase [Ca2]i was inhibited in a dose-dependent
fashion by (S)-4-benzyl-2,2-diphenyl-1,3,2-oxazaborolidine (11).
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were changed to ethyl acetate and benzene. All of these
2-APB analogs were in agreement with the carbon, hydrogen,
and nitrogen analyses and exhibited the predicted functional
group absorptions in the infrared. The NMR findings of these
compounds were in good agreement with the assigned struc-
tures.
One of the intriguing aspects of the structural analysis of
2-APB was observed in the NMR data for this series of
compounds. 2-APB can be visualized as either an open-chain
form or a ring structure (Fig. 1) because of the potential
coordinate covalent bond that might arise between the elec-
tron-rich amine and the electron-deficient boron. The exis-
tence of the ring form is indeed confirmed by the crystal
structure of 2-APB (Retting and Trotter, 1976) which shows
a heterocyclic form in staggered arrays, with each molecule
linked to two others through hydrogen bonds. An examina-
tion of the NMR of 2-APB in d6-DMSO shows that the NH2
protons are indeed in a highly deshielded position (6–7 ppm),
which is also suggestive of a ring rather than of an open-
chain structure. In contrast, the NH2 peak for ethanolamine
is found at 3.3 ppm. This series of 2-APB analogs was de-
signed to examine this ring concept for 2-APB and also to
determine whether a five-membered ring was needed or
whether larger rings would be active (compounds 6 and 7).
The objective was to determine whether chain extension
could resolve the question of the coordination of the NH2
group to boron. The N-methyl (compounds 2 and 3), and
N-butyl (4) analogs, as well as the phenyl (5) and butyl (6)
analogs, all showed the NH and NH2 protons to be highly
deshielded in the 5.9- to 6.8-ppm region in d6-DMSO. This
would suggest that these analogs were also in a similar ring
structure because of the proximity of the NH and NH2 groups
to the electron-deficient boron. However, NMR data for the
hexyl analog (compound 7) in d6-DMSO showed the NH2
protons to be at 3.3 ppm, which is in keeping with an open-
chain structure. Thus, extending the length of the ethanol-
amine side chain in 2-APB by adding two extra carbons (ethyl
to butyl) did not prevent ring formation on the basis of the
NMR data. However, extending the length of the side chain
by another two carbons (butyl to hexyl) prevented the forma-
tion of a ring, on the basis of the NMR data. The reason for
this is not clear; however, the longer side chain decreases the
probability that the nitrogen’s unpaired electrons will be in
close proximity to the boron and hence lessen the likelihood
that a coordinate bond will be formed. The formation of hexyl
dimers would also be less likely to occur because either one or
two coordinate bonds would have to be formed. As seen in
Table 1, hexyl-APB (compound 7), butyl-APB (6), and 2-APB
(1) all have the same ability to inhibit thrombin, despite
hexyl-2-APB (7) not forming a ring. However, we should
caution extrapolating NMR data performed in dimethylsulf-
oxide and biological data in which cells are incubated in an
aqueous buffered salt solution at pH 7.4. Under these aque-
ous conditions, we do not know the proportion of open-chain,
ring, and dimer forms of 2-APB and its analogs.
The presence of a chiral center gives rise to the interesting
splitting pattern of the adjacent protons. A distinctive struc-
tural feature of the two stereoisomers (compounds 11 and 12)
produced in this study was observed in their NMR spectra.
As might be expected, the two R- and S-enantiomers would
necessarily have the same basic NMR patterns, and indeed,
this is observed in d6-DMSO. The NMR data further suggest
that the two NH2 protons in the R- and S-compounds are
essentially nonequivalent. This nonequivalence produces a
triplet arising from the mutual splitting of the two NH2
protons and subsequent splitting by the adjacent proton on
the optically active center. The protons adjacent to the oxy-
gen in these two compounds are also apparently nonequiva-
lent as well and are split into a set of triplets. The protons at
the chiral center of this oxazaborolidine ring system are also
nonequivalent and are therefore split into a set of doublets of
doublets.
Fig. 6. Proposed structure of the acetonitrile adducts of diphenylborinic
acid anhydride. Product A is a diacetonitrile adduct of diphenylborinic
anhydride, and product B is a monoacetonitrile adduct of diphenylborinic
acid that could result from the hydrolysis of adduct A. The structure
shown in C is the result of combining acetonitrile with boron trifluoride,
and this adduct is commercially available (Sigma-Aldrich), whereas ad-
duct D (which has been crystalized) is the result of reaction between
imidazole with boron trifluoride.
TABLE 1
The effect of 2-APB derivatives and nonboron-containing analogs on
thrombin-induced increases in Ca2i in the presence of extracellular
calcium in platelets (predominantly calcium influx)
Abbreviated trivial names are shown for simplicity, together with a designated
number for each compound (Fig. 3).
Compound Name
(Number)
Inhibition of Thrombin Response
at Compound Concentration
100 M 10 M 1 M
%
2-APB (1) 98  6 47  8 16  4
Monomethyl APB (2) 96  1 31  10 7  5
Dimethyl APB (3) 99  1 45  6 15  8
t-Butyl APB (4) 98  1 43  7 11  4
Phenyl APB (5) 96  1 52  6 10  2
Butyl APB (6) 97  3 48  9 8  5
Hexyl APB (7) 98  0 39  9 15  3
Phenyl pyridyl APB (8) —a 74  3 14  7
Methyl pyridyl APB (9) 98  1 55  10 3  12
Glycine ester APB (10) 16  1 2  3 N.D.
(R)-Benzyl APB (11) 97  5 86  8 34  11
(S)-Benzyl APB (12) 91  6 82  7 48  5
Methyloxazolidine (13) 53  7 37  9 15  13
t-Butoxazolidine (14) 83  5 55  5 19  10
Diphenylbutyrolactone (15) 59  4 17  8 7  9
Diphenyltetrahydrofuranb 69  9 62  6 36  8
N.D., not determined.
a Stimulates calcium influx by itself at 100 M.
b From Dobrydneva and Blackmore (2001).
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The rationale for the synthesis of the 2,2-diphenyl-1,3,2-
oxazaborolidine-5-one (compound 10) from the condensation
of diphenylborinic anhydride and the sodium salt of glycine
was taken from the possibility that greater activity might be
achieved by creating a better leaving group within the 2-APB
structure. This would assume that the activity of this class of
compounds may be related to an interaction of some nucleo-
philic moiety on the receptor/channel protein with the highly
polarized 2-APB ring system. This might lead to the subse-
quent displacement of the coordinately bound NH2 group
from the 2-APB moiety and provide for a reversible attach-
ment to the receptor/channel site. By introducing the ester
moiety into the basic 2-APB structure, this type of interac-
tion was expected to be enhanced and may produce a more
effective interaction with the SOCE receptor protein. How-
ever, this compound was a very weak inhibitor of thrombin-
induced Ca2 influx at 100 M (see below).
2-APBDerivatives Block Thrombin-Induced Ca2El-
evation. In the present study, we examined the capacity of
the various analogs to inhibit the ability of thrombin to
increase [Ca2]i in platelets in the presence of extracellular
calcium (Table 1) and in the absence of extracellular calcium
(Table 2). When extracellular calcium was present, approxi-
mately 80 to 90% of the increase in [Ca2]i induced by low
concentrations of thrombin (0.01 units/ml) was caused by
calcium influx (Dobrydneva and Blackmore, 2001). This was
because in the absence of extracellular calcium, the increase
in [Ca2]i induced by thrombin was approximately 10 to 20%
of that observed when extracellular calcium was present.
Modification of the oxazaborolidine ring in the 2-APB an-
alogs does not alter activity substantially, except for the
glycyl ester (compound 10), which had a small 16% inhibitory
activity at 100 M and no activity at lower concentrations
(Table 1). Most of the 2-APB (compound 1) analogs that we
synthesized possessed approximately the same ability to in-
hibit thrombin-induced [Ca2]i increase (Table 1). This in-
cluded phenyl-APB (5), dimethyl-APB (3), monomethyl-APB
(2), t-butyl-APB (4), butyl-APB (6), hexyl-APB (7), and meth-
yl-pyridyl APB (9). Dose responses are shown for 2-APB and
butyl-APB in Fig. 7. Each of these compounds produced be-
tween 96 and 99% inhibition at 100 M, between 31 and 74%
inhibition at 10 M, and between 3 and 16% inhibition at 1
M. Phenyl-pyridyl APB (8) stimulated Ca2 influx at 100
M by itself; however, at 10 and 1 M, it was inhibitory. The
response of 100 M phenyl pyridyl APB to increase [Ca2]i
was approximately 50% of the increase observed with 0.01
units/ml thrombin (Fig. 7). The kinetics of the increase in
[Ca2]i was similar to that observed with thrombin and much
faster than that seen initially with the sarcoplasmic/endo-
plasmic reticulum calcium ATPase (SERCA) inhibitor thap-
sigargin. Thapsigargin initially produces a very small and
slow increase in [Ca2]i, (also Fig. 4 in Dobrydneva and
Blackmore, 2001), then after approximately 1 min, there is a
rapid and large increase in [Ca2]i, probably caused by the
generation of thromboxane, because the response was largely
blocked by treating the platelets with aspirin (data not
shown). Thus, we do not believe that phenyl pyridyl APB was
increasing [Ca2]i by a mechanism involving the inhibition of
SERCA because the kinetics and magnitude of increase in
[Ca2]i are completely different from that seen with the
SERCA inhibitor thapsigargin. We have not examined this
phenomenon any further. There were two analogs that
showed a greater potency than 2-APB to inhibit thrombin:
these were (R)- and (S)-benzyl-APB (compounds 11 and 12)
(Fig. 8).
Previous studies in platelets showed that 2-APB inhibited
calcium influx channels (Diver et al., 2001; Dobrydneva and
Blackmore, 2001). 2-APB also inhibited calcium mobilization
in platelets (Maruyama et al., 1997; Diver et al., 2001; Do-
brydneva and Blackmore, 2001). We therefore also examined
the effects of the 2-APB analogs on thrombin-induced cal-
cium mobilization (Table 2) to determine whether they were
TABLE 2
The effect of 2-APB derivatives and nonboron-containing analogs on
thrombin-induced increases in Ca2i in the absence of extracellular
calcium in platelets (internal calcium mobilization)
Abbreviated trivial names are shown for simplicity together with a designated
number for each compound (Fig. 3).
Compound Name
(Number)
Inhibition of Thrombin Response
at Compound Concentration
100 M 10 M 1 M
%
2-APB (1) 91  2 54  9 36  5
Monomethyl APB (2) 90  2 16  1 3  3
Dimethyl APB (3) 86  6 16  2 0  4
t-Butyl APB (4) 89  2 5  3 4  8
Phenyl APB (5) 96  2 25  4 5  4
Butyl APB (6) 91  4 20  1 6  3
Hexyl APB (7) 90  3 23  4 8  8
Phenyl pyridyl APB (8) 88  6 24  5 10  8
Methyl pyridyl APB (9) —a 16  4 0  5
Glycine ester APB (10) 29  16 0  5 N.D.
(R)-Benzyl APB (11) 100  1 49  9 12  7
(S)-Benzyl APB (12) 95  6 59  11 13  6
Methyloxazolidine (13) 24  9 14  9 0  4
t-Butoxazolidine (14) 94  6 37  2 16  6
Diphenylbutyrolactone (15) 13  7 0  3 N.D.
Diphenyltetrahydrofuranb 51  7 33  7 30  11
N.D., not determined.
a Stimulates calcium release by itself at 100 M.
b From Dobrydneva and Blackmore (2001).
Fig. 7. Effect of phenyl pyridyl APB (8), thrombin, and thapsigargin to
increase [Ca2]i in platelets in the presence of extracellular calcium. The
concentration of phenyl pyridyl APB (8) was 100 M, thapsigargin was
100 nM, and two concentrations of thrombin (0.005 and 0.01 units/ml)
were used. Representative traces are shown.
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more selective at inhibiting either process. When one com-
pares the inhibitory effects of each compound at a 10 M
concentration, 2-APB was the most effective compound at
inhibiting internal release with the exception of (S)-benzyl
APB (compound 12), whereas at a 1 M concentration, 2-APB
was clearly the most effective inhibitor, with a 36% inhibition
(Table 2). When extracellular calcium was present and the
inhibitory effects of each compound at a 10 M concentration
were compared (Table 1), 2-APB possessed an inhibitory
activity that was similar to that of many of the compounds
(e.g., compounds 3, 4, and 6); however, several analogs were
clearly more effective (e.g., compounds 8, 9, 11, 12, and 14).
Several of the analogs were also more effective at the 1 M
concentration (e.g., compounds 11, 12, and 14). Thus, many of
the analogs synthesized had smaller inhibitory effects on
internal release (Table 2) compared with 2-APB, whereas
several analogs were more effective at inhibiting calcium
influx (e.g., compounds 11 and 12). Despite extensive modi-
fications to 2-APB, many of the compounds are able block
both calcium influx and internal release, at least in platelets.
From this limited number of analogs examined, we propose
a common pharmacophore that is responsible for inhibiting
thrombin-induced calcium influx. This pharmacophore con-
sists of two phenyl groups linked to either tetrahedral carbon
or boron. This is confirmed by the fact that replacing the
boron with a carbon such as in compounds 13 and 14 resulted
in inhibitory activity comparable with that seen with most of
the boron-containing analogs. Therefore, it does not seem
that the presence of boron is critical for activity.
All of the most active analogs possessed oxygen at position
1 of the oxazolidine or oxazaborolidine ring. An exception was
compound 15, which had oxygen in a different position in the
ring. Compound 15 was still inhibitory, although it was
clearly less effective than compounds containing oxygen at
position 1; it possessed 59% inhibitory activity at 100 M and
only 17% inhibitory activity at 10 M and no activity at 1 M
(Table 1). In addition, the replacement of the oxygen at
position 1 with a carbonyl group, such as in phenytoin, re-
sulted in only a 22% inhibition at 100 M (Dobrydneva and
Blackmore, 2001). All of the active analogs possessed nitro-
gen at position 3 of the oxazolidine or oxazaborolidine ring.
Methylation (2), dimethylation (3), and t-butylation (4) or
fusing of a benzo ring to the oxazaborolidine ring at this
nitrogen (8 and 9) had very little influence on activity. The
addition of a phenyl group at position 5 of the oxazaborolidine
ring did not influence activity at a concentration of 10 M (5
and 8). At 100 M, compound 8 by itself promoted calcium
influx; however, at 10 M, compound 8 had no effect on
calcium influx by itself, but it produced a good inhibition
(77%) of thrombin, so that this compound was active. The
addition of a carbonyl group at position 5 of the oxazaboroli-
dine ring (10) drastically reduced activity.
Substitution at position 4 of the oxazaborolidine with a
benzyl group (compounds 11 and 12) actually increased the
calcium-blocking activity of 2-APB by approximately 1 order
of magnitude. This is a curious finding because carbon 4 is a
chiral center, which would place the benzyl groups in both
compounds in different orientations relative to the ox-
azaborolidine ring. This lack of stereoselectivity between
compounds could imply that there must be a large hydropho-
bic binding pocket that can tolerate binding of the benzyl
groups when presented in two different orientations (Fig. 9).
Another feature of the boron-containing compounds pre-
sented in this study that should be considered is their ability
to dimerize. However, because comparable calcium-blocking
activity was also observed with carbon analogs of 2-APB
(compounds 13 and 14), which cannot dimerize, dimers do not
contribute to their inhibitory activity. We showed previously
that diphenyl tetrahydrofuran (nonboron analog of 2-APB
without a nitrogen in the tetrahydrofuran ring) possessed the
ability to inhibit thrombin-induced calcium influx (Table 1
and Dobrydneva and Blackmore, 2001). This compound nev-
ertheless was not as effective as 2-APB at 100 M; however,
at lower concentrations, it was more effective than 2-APB
(Table 1). Thus, the absence of nitrogen and boron did not
have a deleterious effect on activity. We also tested another
nonboron analog, 3,3-diphenyl dihydrofuran-2-one (com-
pound 15). This compound was not as effective as 2-APB and
many of its analogs (Table 1). This compound contains an
oxygen at position 4 and a carbonyl at position 3 (relative to
oxygen in 1,3-oxazolidine); therefore, the location of the oxy-
gen and/or the carbonyl group in the ring seems critical for
activity. In addition, the absence of nitrogen in the ring may
contribute to weak activity.
Because the 2-APB analogs possess the potential to dimer-
ize and cyclize because of the formation of an N3B coordi-
Fig. 9. Structure of diphenyl oxazaborolidine and oxazolidine rings;
showing the position of each modification used in the present study.
Atoms in the oxazaborolidine or oxazolidine are numbered 1 through 5
(Table 3). Substituents to the oxazaborolidine and oxazolidine rings are
labeled R1 through R5 (Table 3).
Fig. 8. Dose response of 2-APB (1), butyl APB (6), (S)-benzyl APB (11),
and (R)-benzyl APB (12) to inhibit the ability of thrombin (0.01 units/ml)
to increase [Ca2]i in platelets in the presence of extracellular calcium.
Data are mean  S.E.M. from four separate experiments.
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nate bond, it is also possible that they could also form N3B
coordinate bonds with various amino groups in the calcium
channel. The reaction between acetonitrile and diphenyl-
borinic anhydride (Fig. 6) illustrates this phenomenon. A
variety of nitrogen adducts of BF3 have been previously char-
acterized crystallographically, and these include amines, im-
idazole (Barber et al., 2005; Fig. 6D), pyridine, and acetoni-
trile (Swanson et al., 1969; Fig. 6C) adducts (Barber et al.,
2005). It is therefore conceivable that the boron analogs
synthesized in the present study can also form coordinate
bonds with amino acids (either N3B or O3B). There is
precedence for the boron-containing organic molecule bort-
ezomib forming a coordinate bond with the N-terminal thre-
onine residue of the 26S proteasome (Pekol et al., 2005). If
N3B coordinate bonds were to occur in the cell, then these
boron-containing compounds would perhaps bind more
tightly to the calcium channel than their nonboron contain-
ing counterparts because of coordinate bond formation. Table
3 summarizes all of the modifications to 2-APB that were
prepared and what influence they had on activity. It should
be pointed out that in the present study, we have not at-
tempted to alter the diphenyl groups to determine whether
such modifications would influence activity.
This study shows that 2-APB can undergo significant mod-
ifications that have little effect on its ability to inhibit throm-
bin-induced Ca2 influx in human platelets. However, we did
find that two benzyl derivatives (compounds 11 and 12) were
more potent than the parent 2-APB compound. This gives us
encouragement that further modifications to the 2-APB mol-
ecule can increase its potency even further. We did find
previously that diphenyltetrahydrofuran (Dobrydneva and
Blackmore, 2001; Table 1) produced approximately 70% in-
hibition of the thrombin response at 100 M; however, the
IC50 value was approximately 1 M. Thus, diphenyltetrahy-
drofuran was the most potent inhibitor that we have found so
far, although it was not as effective as 2-APB and many of its
analogs, which produce approximately 100% inhibition at
100 M (Table 1).
As indicated by Bootman et al. (2002), 2-APB influences
calcium homeostasis in a variety of cells by several different
mechanisms. These include the original finding that 2-APB
inhibits calcium release via IP3Rs (Maruyama et al., 1997),
although this effect is cell-specific (Soulsby andWojcikiewicz,
2002). In addition, 2-APB also inhibits IP3Rs ubiquitination
and proteasomal degradation in some cells (Soulsby and
Wojcikiewicz, 2002). 2-APB has also been shown to inhibit
smooth endoplasmic reticulum calcium ATPase pumps in
some cells, thus causing a slow increase in [Ca2]i (Bootman
et al., 2002). In addition, 2-APB prevents mitochondria from
releasing Ca2 (Prakriya and Lewis, 2001). The best effect of
2-APB so far characterized is its ability to inhibit store-
mediated calcium influx in a variety of cells, including plate-
lets (Dobrydneva and Blackmore, 2001; Bootman et al.,
2002). There are many TRP channels that are inhibited by
2-APB in the 10 to 100 M range, and these include TRPC1,
TRPC3, TRPC5, TRPC6, TRPV6, TRPM3, TRPM7, TRPM8,
and TRPP2 (Xu et al., 2005). Other members of the TRP
channels are either activated or unaffected 2-APB. 2-APB
also has been shown to modulate the store-operated calcium
release-activated Ca2 channels (e.g., Braun et al., 2001) and
the Mg2-inhibited cation channel (Kozak et al., 2002;
Prakriya and Lewis, 2002).
It is of interest to compare the effects of the 2-APB analogs
used in the current study on other parameters that influence
[Ca2]i in a variety of cell types. Different 2-APB analogs
may have selective inhibitory or stimulatory effects on the
various TRP channels, and they are likely to be very useful in
elucidating the nature of the TPR channels present in vari-
ous cells.
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